Management Sciences for Health President and CEO Appointed to the RBM Partnership to End Malaria Board of Directors

January 03, 2022

Management Sciences for Health President and CEO Appointed to the RBM Partnership to End Malaria Board of Directors

Arlington, VA—January 3, 2022—Management Sciences for Health (MSH) President and CEO Marian W. Wentworth has been appointed to the RBM Partnership to End Malaria Board of Directors for a three-yearterm. The appointment comes as global deaths from malaria rose by 69,000 in 2020, with two-thirds of deaths stemming from disruptions related to the COVID-19 pandemic. Efforts to prevent and treat the infectious disease are more urgent than ever as progress toward global reduction goals stalls.

Launched by the World Health Organization, UNICEF, UNDP, and the World Bank in 1998, the Roll Back Malaria partnership is the global platform for coordinated action against malaria. Its role is to convene, coordinate, and facilitate communication among more than 500 partners, including malaria endemic countries, their bilateral and multilateral development partners, the private sector, community-based organizations, foundations, and research and academic institutions. Since its inception, the partnership has mobilized resources that have been deployed to save more than 7 million lives.

For more than three decades, MSH has teamed with national malaria control programs, donors, and local stakeholders in dozens of countries to fight malaria. MSH is a partner of the US President’s Malaria Initiative for States (PMI-S); the Global Fund to Fight AIDS, Tuberculosis and Malaria; the US Agency for International Development (USAID); the Bill & Melinda Gates Foundation; and others to scale proven interventions while building capacity across health systems, ensuring access to lifesaving treatments and supporting health providers. 

Using tools such as data analysis, community-level preventive treatment, and digital health apps that expand national and local capacity, MSH helps deliver solutions for health systems to ensure access to high-impact malaria prevention and case management services. Efforts include partnering with Madagascar’s Ministry of Public Health to develop and roll out a mobile app to track cases and target diagnostics and working with community health workers in Nigeria to deliver antimalarial medicine during the rainy season.

Wentworth, a member of WHO’s Malaria Vaccine Advisory Committee, will bring decades of hands-on experience to the board, having worked in both the private and NGO sectors, giving her a unique perspective in designing and executing effective public health interventions. Prior to joining MSH in 2017, Wentworth managed Merck & Company’s global strategy for marketing, manufacturing, and research for a $6 billion vaccine business. While at Merck, she led the launch of the world’s first cervical cancer vaccine and managed a broad portfolio of adult vaccines. As part of her leadership at MSH, Wentworth also chairs the board of MedSource, a Kenyan pharmaceutical group purchasing organization, and serves on the board of the needle-free vaccine delivery firm PharmaJet.

Read RBM Partnership to End Malaria’s announcement here.